UFP Technologies, Inc. (UFPT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$288.79+0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · UFPT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 48.3% |
| Our one-year growth estimate | diamond | 8.0% |
Growth built into the price is above our model estimate.
The price assumes 40.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
UFPT — General Counsel transition
Dated 2026-05-26
General Counsel, Secretary, and Senior Vice President of Human Resources — Christopher P. Litterio: General Counsel, Secretary, and Senior Vice President of Human Resources plans to retire after a period of transition.
Why it matters: New buildings will help meet the need for robotic surgery and patient care.
Supportive ifBuildings in La Romana and Santiago are open and making products.
Worry ifDelays in opening or problems after opening could be an issue.
Why it matters: Stable margins show that costs are managed well during expansion.
Supportive ifGross margin remains above 29% in Q3.
Worry ifGross margin falls below 28% in Q3.
Why it matters: Improving cash flow is crucial for funding growth. A rise above $10M would show progress.
Supportive ifCash flow from operations reported above $10M in Q2.
Worry ifCash flow from operations remains below $10M in Q2.
Why it matters: Strong sales growth shows that UFP's growth plans are working and that there is demand.
Supportive ifQ3 sales growth exceeds 15% year over year.
Worry ifQ3 sales growth is below 10% year over year.
Why it matters: New facilities will help meet demand in robotic surgery. They will also increase capacity.
Supportive ifThe new facilities in the Dominican Republic will be running by the end of Q2 2026.
Worry ifOne or both facilities are delayed past Q2 2026.
Why it matters: New acquisitions could improve UFP's skills and help growth in MedTech.
Supportive ifA new acquisition was announced that fits the growth plan.
Worry ifNo new acquisitions announced in the next quarter.
Why it matters: Organic sales growth is key to UFP's growth strategy. A drop signals potential issues.
Worry ifOrganic sales growth for Q3 comes in below 6.8%.
Less concerning ifOrganic sales growth for Q3 exceeds 6.8%.
Why it matters: Higher EPS growth shows good cost management and better profits.
Supportive ifQ2 adjusted EPS growth exceeds 1.4% year over year.
Worry ifQ2 adjusted EPS growth falls below 1.4% year over year.
Why it matters: If revenue growth is low, it may mean demand is weak or there are issues.
Worry ifQ2 revenue growth is reported below 4.1% year over year.
Less concerning ifQ2 revenue growth exceeds 4.1% year over year.
Why it matters: New acquisitions may improve UFP's market position and growth. Announcements show progress.
Supportive ifAnnouncement of a new acquisition that fits UFP's growth strategy.
Worry ifNo new acquisitions announced by the end of Q2.
Why it matters: Strong growth in MedTech sales is key to overall revenue. It shows demand in a high-growth segment.
Supportive ifMedTech sales growth exceeds 5% year over year in Q3.
Worry ifMedTech sales growth is below 0% year over year in Q3.
Why it matters: If SG&A costs go up a lot, it could hurt margins and profits.
Worry ifSG&A expenses exceed 15% of total sales in Q3.
Less concerning ifSG&A expenses remain below 12% of total sales in Q3.
Why it matters: Slower growth in operating income may show trouble in managing costs or demand.
Worry ifOperating income growth is below 10% year over year in Q3.
Less concerning ifOperating income growth exceeds 15% year over year in Q3.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$131 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $387 loss on $10,000 · 3.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,069 loss on $10,000 · 30.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.